Acquired immune response to oncogenic human papillomavirus associated with prophylactic cervical cancer vaccines

Mark H. Einstein

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Human papillomavirus (HPV) is a common infection among women and a necessary cause of cervical cancer. Oncogenic HPV types infecting the anogenital tract have the potential to induce natural immunity, but at present we do not clearly understand the natural history of infection in humans and the mechanisms by which the virus can evade the host immune response. Natural acquired immune responses against HPV may be involved in the clearance of infection, but persistent infection with oncogenic virus types leads to the development of precancerous lesions and cancer. B cell responses are important for viral neutralization, but antibody responses in patients with cervical cancer are poor. Prophylactic vaccines targeting oncogenic virus types associated with cervical cancer have the potential to prevent up to 80% of cervical cancers by targeting HPV types 16 and 18. Clinical data show that prophylactic vaccines are effective in inducing antibody responses and in preventing persistent infection with HPV, as well as the subsequent development of high-grade cervical intraepithelial neoplasia. This article reviews the known data regarding natural immune responses to HPV and those developed by prophylactic vaccination.

Original languageEnglish (US)
Pages (from-to)443-451
Number of pages9
JournalCancer Immunology, Immunotherapy
Volume57
Issue number4
DOIs
StatePublished - Apr 2008

Fingerprint

Cancer Vaccines
Uterine Cervical Neoplasms
Infection
Oncogenic Viruses
Antibody Formation
Vaccines
Viral Antibodies
Human papillomavirus 18
Cervical Intraepithelial Neoplasia
Human papillomavirus 16
Innate Immunity
Vaccination
B-Lymphocytes
Viruses
Neoplasms

Keywords

  • CIN
  • HPV
  • Immunity
  • Persistent infection
  • Viral neutralization

ASJC Scopus subject areas

  • Cancer Research
  • Immunology
  • Oncology

Cite this

Acquired immune response to oncogenic human papillomavirus associated with prophylactic cervical cancer vaccines. / Einstein, Mark H.

In: Cancer Immunology, Immunotherapy, Vol. 57, No. 4, 04.2008, p. 443-451.

Research output: Contribution to journalArticle

@article{12c0605300924fcd9f460fa3191a15fa,
title = "Acquired immune response to oncogenic human papillomavirus associated with prophylactic cervical cancer vaccines",
abstract = "Human papillomavirus (HPV) is a common infection among women and a necessary cause of cervical cancer. Oncogenic HPV types infecting the anogenital tract have the potential to induce natural immunity, but at present we do not clearly understand the natural history of infection in humans and the mechanisms by which the virus can evade the host immune response. Natural acquired immune responses against HPV may be involved in the clearance of infection, but persistent infection with oncogenic virus types leads to the development of precancerous lesions and cancer. B cell responses are important for viral neutralization, but antibody responses in patients with cervical cancer are poor. Prophylactic vaccines targeting oncogenic virus types associated with cervical cancer have the potential to prevent up to 80{\%} of cervical cancers by targeting HPV types 16 and 18. Clinical data show that prophylactic vaccines are effective in inducing antibody responses and in preventing persistent infection with HPV, as well as the subsequent development of high-grade cervical intraepithelial neoplasia. This article reviews the known data regarding natural immune responses to HPV and those developed by prophylactic vaccination.",
keywords = "CIN, HPV, Immunity, Persistent infection, Viral neutralization",
author = "Einstein, {Mark H.}",
year = "2008",
month = "4",
doi = "10.1007/s00262-007-0440-y",
language = "English (US)",
volume = "57",
pages = "443--451",
journal = "Medical Oncology and Tumor Pharmacotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "4",

}

TY - JOUR

T1 - Acquired immune response to oncogenic human papillomavirus associated with prophylactic cervical cancer vaccines

AU - Einstein, Mark H.

PY - 2008/4

Y1 - 2008/4

N2 - Human papillomavirus (HPV) is a common infection among women and a necessary cause of cervical cancer. Oncogenic HPV types infecting the anogenital tract have the potential to induce natural immunity, but at present we do not clearly understand the natural history of infection in humans and the mechanisms by which the virus can evade the host immune response. Natural acquired immune responses against HPV may be involved in the clearance of infection, but persistent infection with oncogenic virus types leads to the development of precancerous lesions and cancer. B cell responses are important for viral neutralization, but antibody responses in patients with cervical cancer are poor. Prophylactic vaccines targeting oncogenic virus types associated with cervical cancer have the potential to prevent up to 80% of cervical cancers by targeting HPV types 16 and 18. Clinical data show that prophylactic vaccines are effective in inducing antibody responses and in preventing persistent infection with HPV, as well as the subsequent development of high-grade cervical intraepithelial neoplasia. This article reviews the known data regarding natural immune responses to HPV and those developed by prophylactic vaccination.

AB - Human papillomavirus (HPV) is a common infection among women and a necessary cause of cervical cancer. Oncogenic HPV types infecting the anogenital tract have the potential to induce natural immunity, but at present we do not clearly understand the natural history of infection in humans and the mechanisms by which the virus can evade the host immune response. Natural acquired immune responses against HPV may be involved in the clearance of infection, but persistent infection with oncogenic virus types leads to the development of precancerous lesions and cancer. B cell responses are important for viral neutralization, but antibody responses in patients with cervical cancer are poor. Prophylactic vaccines targeting oncogenic virus types associated with cervical cancer have the potential to prevent up to 80% of cervical cancers by targeting HPV types 16 and 18. Clinical data show that prophylactic vaccines are effective in inducing antibody responses and in preventing persistent infection with HPV, as well as the subsequent development of high-grade cervical intraepithelial neoplasia. This article reviews the known data regarding natural immune responses to HPV and those developed by prophylactic vaccination.

KW - CIN

KW - HPV

KW - Immunity

KW - Persistent infection

KW - Viral neutralization

UR - http://www.scopus.com/inward/record.url?scp=38649121795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38649121795&partnerID=8YFLogxK

U2 - 10.1007/s00262-007-0440-y

DO - 10.1007/s00262-007-0440-y

M3 - Article

VL - 57

SP - 443

EP - 451

JO - Medical Oncology and Tumor Pharmacotherapy

JF - Medical Oncology and Tumor Pharmacotherapy

SN - 0340-7004

IS - 4

ER -